Stifel analyst Rick Wise raised the firm’s price target on Pulmonx to $17 from $15 and keeps a Buy rating on the shares. y, Q4 U.S. growth accelerated to about 45% year-over-year and 16% quarter-over-quarter, driven by continued commercial execution and market development initiatives, the analyst tells investors in a post-earnings note. Looking ahead to 2024, management provided initial full-year sales guidance at $81M-$84M, ahead of the firm’s $80.1M estimate, the analyst noted.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on LUNG:
- Pulmonx Announces Executive Leadership Transition and Board Changes
- Pulmonx Announces Retirement of CEO Glen French and Appointment of Industry Veteran Steve Williamson as President and Chief Executive Officer
- Pulmonx Reports Fourth Quarter and Full Year 2023 Financial Results
- Pulmonx to Report Fourth Quarter and Full Year 2023 Financial Results on February 21, 2024
